The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling;Cancer Prevention and Control;Drug Discovery, Delivery and Translational Therapeutics;and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement;Biostatistics;Cancer Research Informatics;Clinical Research and Data Management;Flow Cytometry and Cell Sorting;and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.

Public Health Relevance

As a state with the second highest all-site cancer Incidence rate and the highest rate of cancer deaths in the United States, Kentucky suffers from particularly intractable cancer health challenges. The Markey Cancer Center seeks support to further develop its capacities in cutting-edge science to accelerate bench to bedside translational outcomes, which will reduce this serious health disparity and significantly impact our patients, our state, and the nation through cancer prevention, patient care, and research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA177558-01S1
Application #
8709073
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2013-07-08
Project End
2018-06-30
Budget Start
2013-07-08
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$75,000
Indirect Cost
$25,000
Name
University of Kentucky
Department
Surgery
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356
Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409
Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228
Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5
Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174
Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258
Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887
Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837
Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330
Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615

Showing the most recent 10 out of 281 publications